Results 21 to 30 of about 85,257 (242)

Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis

Heliyon
Bevacizumab is widely used in various clinical indications, but investigations into its optimal dosage for treating CNS metastases remain limited. The BEEP regimen, comprising bevacizumab, etoposide, and cisplatin, has recently demonstrated promising ...
Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo   +6 more
doaj   +1 more source

Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension

Case Reports in Gastroenterology, 2017
Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension
Luigi F. Bertoli, Pauline L. Lee, Lauren Lallone, James C. Barton   +3 more
doaj   +1 more source

Combining Bevacizumab with Endostatin Gets Better Antitumor Efficacy in Vivo 
in Lung Cancer Animal Model

Chinese Journal of Lung Cancer, 2013
Background and objective The aim of this study is to investigate difference of antiangiogenesis ablility and interaction about bevacizumab and endostatin in vivo in lung cancer animal model.
Niu NIU, Baolan LI, Chaoyang LIU, Ying HU, Xuebing LI, Jie LI, Heling SHI, Haiqing ZHANG   +7 more
doaj   +1 more source

Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro

International Journal of Nephrology, 2021
Molecular mechanisms underlying the nephrotoxicity associated with bevacizumab are unclear. Endothelin-1 (ET-1) is involved in podocyte injury and proteinuria, and its level increases in most cases of kidney disorders.
Satoru Nihei, Junichi Asaka, Hiroaki Takahashi, Kenzo Kudo   +3 more
doaj   +1 more source

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Medicina, 2021
Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab ...
Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Nozomi Tani, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Daishiro Kato, Takayuki Takeda   +9 more
doaj   +1 more source

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports

Medicina
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim   +4 more
doaj   +1 more source

Bevacizumab for glioblastoma

Therapeutics and Clinical Risk Management, 2015
Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic ...
openaire   +5 more sources

The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi, Maria Carmen Affinita, Giulia Fichera, Luisa Santoro, Angela Scagnellato, Calogero Virgone, Elena Poli, Gianni Bisogno   +7 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study

Clinical Medicine Insights: Oncology
Background: The bevacizumab biosimilar (Encoda), which was approved by the National Medical Products Administration (NMPA) in China in 2019, is a biosimilar of bevacizumab.
Han Shan, Mengmeng Wang, Shuohan Huang, Hongyue Liu, Jiyong Liu, Qiong Du   +5 more
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source